Evercore ISI Group Maintains Outperform on Insmed, Raises Price Target to $170

Benzinga · 2d ago
Evercore ISI Group analyst Josh Schimmer maintains Insmed (NASDAQ:INSM) with a Outperform and raises the price target from $160 to $170.